Published in Genetics and Environmental Business Week, April 5th, 2007
"Based on the data presented at TAT 2007 and the Keystone Symposia 'Molecular Targets for Cancer' meetings, we believe that SNS-314 has a compelling preclinical profile and merits full clinical development. In diverse xenograft models, this anticancer agent demonstrates good activity that is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.